Spartano Nicole L, Sultana Naznin, Lin Honghuang, Cheng Huimin, Lu Sophia, Fei David, Murabito Joanne M, Walker Maura E, Wolpert Howard A, Steenkamp Devin W
Boston University's and National Heart, Lung, and Blood Institute's Framingham Heart Study, Framingham, MA 01702, USA.
Section of Endocrinology, Diabetes, Nutrition, and Weight Management, Boston University Chobanian and Avedisian School of Medicine (BUCASM) and Boston Medical Center, Boston, MA 02118, USA.
J Clin Endocrinol Metab. 2025 Mar 17;110(4):1128-1134. doi: 10.1210/clinem/dgae626.
Continuous glucose monitor (CGM) companies are beginning to market these sensors to populations without diabetes, but the range of CGM values clinicians should expect to see for this population is unclear because there have been no large studies reporting these ranges.
This work aimed to report the physiological range of CGM time in range values observed across glycemic status, including individuals without diabetes, to serve as a reference for clinicians.
The Framingham Heart Study, a prospective cohort study, was conducted among community-dwelling adults with normoglycemia (n = 560), prediabetes (n = 463), and diabetes (n = 152). We conducted a cross-sectional investigation in participants who wore a Dexcom G6 Pro CGM (in blinded mode) for 7 or more complete days. Main outcome measures included CGM metrics including mean glucose and time spent in glucose ranges.
Normoglycemic participants (mean age 58.5 years, 64.5% women, 93.3% non-Hispanic White) spent 87.0% time in the 70 to 140 mg/dL CGM range, and, on average, more than 15 minutes/day (1.2% time) at more than 180 mg/dL. Furthermore, normoglycemic participants spent approximately 3 hours/day (12.1% time) with CGM glucose at more than 140 mg/dL. On average, participants with prediabetes and diabetes spent 77.1% and 46.2% of time in the 70 to 140 mg/dL range, respectively.
Our results contribute to the understanding of the physiological CGM range in more than 1000 participants without diabetes. These results are also important for clinicians to reference as CGM sensors become more widely accessible to people without known diabetes.
连续血糖监测（CGM）公司开始向非糖尿病患者群体推销这些传感器，但由于尚无大型研究报告该群体的CGM值范围，临床医生对于该群体预期会看到的CGM值范围并不清楚。
这项研究旨在报告在不同血糖状态（包括无糖尿病个体）中观察到的CGM处于目标范围内时间的生理范围，为临床医生提供参考。
在弗雷明汉心脏研究中，对社区居住的血糖正常者（n = 560）、糖尿病前期患者（n = 463）和糖尿病患者（n = 152）进行了一项前瞻性队列研究。我们对佩戴德康G6 Pro CGM（盲法模式）达7天或更长完整天数的参与者进行了横断面调查。主要结局指标包括CGM指标，如平均血糖和处于血糖范围内的时间。
血糖正常的参与者（平均年龄58.5岁，64.5%为女性，93.3%为非西班牙裔白人）87.0%的时间CGM值处于70至140mg/dL范围，平均每天有超过15分钟（1.2%的时间）CGM值高于180mg/dL。此外，血糖正常的参与者约3小时/天（12.1%的时间）CGM血糖值高于140mg/dL。糖尿病前期和糖尿病参与者平均分别有77.1%和46.2%的时间CGM值处于70至140mg/dL范围。
我们的研究结果有助于了解1000多名无糖尿病参与者的生理CGM范围。随着CGM传感器在无已知糖尿病的人群中更广泛地普及，这些结果对临床医生也具有重要的参考价值。
